問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

顏學偉
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏學偉

List

35Cases

2009-02-15 - 2012-09-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2012-12-01 - 2016-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Study ended8Sites

2014-11-01 - 2019-05-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Condition/Disease

    Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Terminated9Sites

2014-05-01 - 2019-03-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

  • Condition/Disease

    Acute Heart Failure Patients

  • Test Drug

    REASANZ

Participate Sites
10Sites

Terminated10Sites

2011-04-01 - 2019-04-26

Phase III

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

  • Condition/Disease

    Atherosclerosis

  • Test Drug

    Canakinumab / ACZ885

Participate Sites
14Sites

Terminated14Sites

2009-07-01 - 2012-07-27

Phase III

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure

  • Condition/Disease

    Acute Decompensated Heart Failure

  • Test Drug

    Aliskiren(SPP100)/Rasilez®

Participate Sites
5Sites

Terminated5Sites

2009-05-01 - 2015-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2013-10-31 - 2015-06-30

Phase II

A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)

  • Condition/Disease

    Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)

  • Test Drug

    BAY 1021189 immediate-release (IR) tablet

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2013-10-31 - 2015-10-30

Phase II

A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)

  • Condition/Disease

    Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)

  • Test Drug

    BAY 1021189

Participate Sites
5Sites

Terminated5Sites

2014-04-15 - 2017-12-31

Phase III

A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

  • Condition/Disease

    Antidote for dabigatran

  • Test Drug

    Idarucizumab (BI 655075)

Participate Sites
5Sites

Terminated5Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB